Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PRQR 
ProQR Therapeutics BV (PRQR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PRQR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 66.32% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 147.30M USD | Price to earnings Ratio - | 1Y Target Price 10.67 |
Price to earnings Ratio - | 1Y Target Price 10.67 | ||
Volume (30-day avg) 611501 | Beta 0.24 | 52 Weeks Range 1.25 - 4.62 | Updated Date 04/1/2025 |
52 Weeks Range 1.25 - 4.62 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-13 | When - | Estimate -0.154 | Actual -0.0991 |
Profitability
Profit Margin -142.05% | Operating Margin (TTM) -226.9% |
Management Effectiveness
Return on Assets (TTM) -12.45% | Return on Equity (TTM) -42.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3931938 | Price to Sales(TTM) 7.54 |
Enterprise Value -3931938 | Price to Sales(TTM) 7.54 | ||
Enterprise Value to Revenue 3.54 | Enterprise Value to EBITDA -2.1 | Shares Outstanding 105213000 | Shares Floating 67962032 |
Shares Outstanding 105213000 | Shares Floating 67962032 | ||
Percent Insiders 18.06 | Percent Institutions 53.87 |
Analyst Ratings
Rating 4.43 | Target Price 9.17 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ProQR Therapeutics BV
Company Overview
History and Background
ProQR Therapeutics NV, founded in 2012, is a biopharmaceutical company focused on developing RNA therapies for rare genetic diseases. It has evolved from focusing on cystic fibrosis to expanding its pipeline to include other genetic conditions.
Core Business Areas
- RNA Therapeutics Development: Focuses on developing RNA-based therapies targeting the underlying genetic causes of rare diseases.
- Preclinical and Clinical Research: Conducts research and clinical trials to evaluate the safety and efficacy of its therapeutic candidates.
Leadership and Structure
Details regarding ProQR Therapeutics NV's leadership team can be found on their website and in their SEC filings. They have a typical structure for a biopharmaceutical company with a CEO, CFO, CSO, and other key executives.
Top Products and Market Share
Key Offerings
- Sepofarsen (QR-110): Sepofarsen is ProQR's most advanced product candidate, targeting Leber's congenital amaurosis 10 (LCA10) due to the p.Arg15His mutation in the CEP290 gene. Market share data is not publicly available due to it being an investigational drug. Competitors are companies working on gene therapies for inherited retinal diseases.
- Axiomer platform: Axiomer is ProQR's RNA editing platform which they plan to use to develope more drugs. There is no market share data due to it being a platform in early stages. Competitors are companies working on gene editing technologies
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with increasing focus on personalized medicine and gene therapies. The regulatory landscape is stringent, requiring extensive clinical trials and approvals.
Positioning
ProQR is positioned as a company specializing in RNA therapies for rare genetic diseases. Its competitive advantage lies in its expertise in RNA technology and its focus on specific genetic mutations.
Total Addressable Market (TAM)
The total addressable market for RNA therapies is estimated to be in the billions of dollars and growing, given the potential to address a wide range of genetic diseases. ProQR is targeting niche markets within this broader market.
Upturn SWOT Analysis
Strengths
- Specialized expertise in RNA therapeutics
- Focus on rare genetic diseases with unmet medical needs
- Advancing clinical programs with promising results
- Proprietary technology platforms like Axiomer
Weaknesses
- High R&D costs and long development timelines
- Dependence on clinical trial outcomes
- Competition from larger pharmaceutical companies
- Limited commercialized products
Opportunities
- Expansion of pipeline into new genetic diseases
- Strategic partnerships with larger pharmaceutical companies
- Potential for breakthrough therapies with significant market potential
- Leveraging technological advancements in RNA delivery
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from novel therapies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- IONS
- SGEN
- ALNY
Competitive Landscape
ProQR faces competition from larger pharmaceutical companies with more resources and established pipelines. Its competitive advantage lies in its specialized expertise and focus on specific genetic mutations.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: ProQR's growth has been driven by advancements in its clinical programs and the expansion of its technology platform.
Future Projections: Future growth depends on the success of clinical trials, regulatory approvals, and strategic partnerships.
Recent Initiatives: Recent initiatives include advancing its clinical programs, expanding its pipeline, and pursuing strategic partnerships.
Summary
ProQR Therapeutics is a biotechnology company specializing in RNA therapies for rare genetic diseases. They are currently in development stages which means they have a very high risk, high reward investment. They compete with larger better funded companies but are in a high TAM industry. They must look out for clinical trail failures that could wipeout the company in an instant.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
BEAM
Beam Therapeutics Inc
BEAM
Beam Therapeutics Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
IONS
Ionis Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- ProQR Therapeutics BV website
- SEC filings
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProQR Therapeutics BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-09-18 | Founder, CEO & Member of Management Board Mr. Daniel Anton de Boer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 166 | Website https://www.proqr.com |
Full time employees 166 | Website https://www.proqr.com | ||
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.